Acute Myeloid Leukemia Clinical Trial
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
Summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Full Description
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and Acute Mixed-Phenotype Leukemia (MPAL) who may or may not be on Antifungals.
Eligibility Criteria
Key Inclusion Criteria:
Age ≥ 18 years.
Individuals with histologically or pathologically confirmed diagnosis of relapsed or refractory AML, ALL, or MPAL with documented FLT3 mutation, and/or Individuals with histologically or pathologically confirmed diagnosis of their malignancy with wild-type FLT3 (including those with MLL1-R and NPM1 mutations).
ECOG performance status of 0-2.
Adequate liver and renal function
Adhere to the CYP3A4 inhibitor concomitant therapy use requirements, as follows:
Arm A: Participants must not have received a moderate or strong CYP3A4 inhibitor for at least 7 days prior to enrollment and are not anticipated to require such agents in the near term (for at least 4 weeks).
Arm B: Participants must have received a necessary azole antifungal(s) that is a moderate or strong CYP3A4 inhibitor (excluding other moderate or strong CYP3A4 inhibitor[s]) for at least 7 days prior to enrollment and be able to continue such azole antifungal(s) while on BMF-500 treatment for at least 4 weeks.
Key Exclusion Criteria:
Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including transient ischemic attack within 6 months prior to the first dose of the trial intervention.
WBC count >50,000/µL (uncontrollable with cytoreductive therapy).
Women who are pregnant or lactating or plan to become pregnant.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 24 Locations for this study
Phoenix Arizona, 85054, United States
Duarte California, 91010, United States
Los Angeles California, 90095, United States
Sacramento California, 95817, United States
San Francisco California, 94143, United States
Denver Colorado, 80218, United States
Jacksonville Florida, 32224, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60637, United States
Lexington Kentucky, 40536, United States
Rochester Minnesota, 55902, United States
Hackensack New Jersey, 07601, United States
Bronx New York, 10467, United States
Buffalo New York, 14203, United States
New Hyde Park New York, 11042, United States
New York New York, 10065, United States
Greenville North Carolina, 27858, United States
Cleveland Ohio, 44195, United States
Oklahoma City Oklahoma, 73104, United States
Dallas Texas, 75251, United States
Houston Texas, 77030, United States
Gainesville Virginia, 20155, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?